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Abstract A new genotyping-based DNA assay (Digene
LQ) was developed recently. The primary aim was to
assess the distribution of HPV types using this new assay in
atypical squamous cells of undeterminate significance
(ASCUS). The secondary aim was to correlate the HPV
types with the severity of the disease. The study population
comprised 376 ASCUS women. The women were all
Hybrid Capture II (HCII) positive and were admitted in
three European referral gynecology clinics between 2007
and 2010. A colposcopy with histological examination was
performed in all these patients. HPV 16 was typed in 40 %
of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and
18 % of patients had mixed genotypes. Patients aged over
30 more often had the HPV 16 genotype than patients aged
under 30 (29 % vs. 11 %, chi-square test p \ 0.001). The
risk of cervical intra-epithelial neoplasia of grade 2 or more
(CIN2 ?) when HPV 18 positive is lower than the proba-
bility associated with HPV 16 or HPV 31: 28 % vs. 58 %
and 52 %, respectively (chi-square test, p = 0.005 and
p = 0.05, respectively). The Digene LQ, a new sequence-
specific hybrid capture sample preparation, is fast and
efficient and allows high-throughput genotyping of 18 HR
HPV types by PCR compared to traditional non-sequence-
specific sample preparation methods.
Introduction
High-risk types of human papillomavirus (HPV) are
causative agents for cervical cancer. The effectiveness of
the cervical screening program could be improved by
testing for the DNA of high-risk types of HPV as a primary
screening tool [1–3]. More than 200 genotypes have been
identified, among which about 40 can infect the mucosa of
the anogenital tract. HPV genotypes are classified into
‘‘high-risk’’ HPV (HR HPV), ‘‘probable high-risk’’ HPV,
and ‘‘low-risk’’ HPV (LR-HPV) genotypes [3–5]. The
classification has been updated, based on epidemiological
data. The HR group includes 15 HPV genotypes (types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) that
proved to be associated with cervical cancer, while the LR
group includes 12 HPV genotypes (types 6, 11, 40, 42, 43,
44, 54, 61, 70, 72, 81, and CP6108) that are not potentially
oncogenic and not involved in the development of cervical
cancer [6, 7]. In a recent study, Bouvard et al. [8] suggested
that the following 12 genotypes might be HR types: types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. Three
HPV genotypes (types 26, 53, 66) are classified as probable
HR genotypes because their association with cervical
cancer is very difficult to assess, giving a low number of
related cases [9]. Some authors have proposed that HPV
genotypes 26, 53, 66, 73, and 82 should be added to the
HR genotypes classification associated with cervical cancer
[5, 10].
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In view of the increasing importance of HPV genotyp-
ing, it is important to develop robust, high-throughput
assays. Recently, HPV genotyping tests have been pre-
sented as relevant for management of screened women, in
order to identify which HPV-positive women have persis-
tent oncogenic HPV infection [10, 11]. Studies have shown
that a single positive test result from either type 16 or type
18 has high predictive value for cervical intra-epithelial
neoplasia grade 2 or more (CIN2?) [4, 5, 12]. US guide-
lines recommend genotyping for type 16 and type 18 in HR
HPV-positive women over 30 years of age with normal
PAP to determine whether immediate colposcopy is needed
[13]. Several genotyping assays have been developed based
on different technologies (reverse dot blot, biotinylated
MY09/11, DNA-chip technology). These commercial
assays allow the detection of 37 HPV genotypes (LA,
Roche), 24 HPV genotypes (Papillocheck HPV-screening
test, Greiner Bio-One), 35 HPV genotypes (Clinical
Arrays, CLART Genomica), and 28 HPV genotypes
(INNO-LiPA HPV Genotyping, Innogenetics) [14–17].
The most used genotyping assay, LA, correlates in per-
formance with the HPV Hybrid Capture II (HCII) test for
detection of CIN 2? [18–20].
A novel, commercial system (Digene LQ) for the
identification of 18 HR HPV types on GP5?/6?-PCR
products was developed and compared analytically to the
established Reverse Line Blot (RLB) genotyping assay
[21]. Godinez et al. [22] recently performed clinical vali-
dation of QIAGEN LQ in women [ 40 years old. How-
ever, no clinical validation has been performed in women
aged [ 18 years old.
The primary aim of this study was to assess the distri-
bution of HPV types using this new assay. The secondary
aim was to correlate the HPV types to the severity of the
disease (cytology and histology) with calculation of prob-
abilities of CIN2? by HPV type.
Materials and methods
Patients
The study population comprised 376 atypical squamous
cells of undetermined significance (ASCUS) women who
were admitted to three European referral gynecology
clinics between 2007 and 2010: 158 patients from Madrid
(Spain), 123 from Marseille (France), and 95 from Milan
(Italy). Criteria for eligibility were age between 18 and
60 years, abnormal cervical smears and HC-II-positive
results, and referral for colposcopy with histology. Before
colposcopy, a cervical sample was obtained using the
ThinPrep method (Cytyc France Sarl, Roissy, France). The
cervical scrapes were collected with the PreservCyt
transport medium (Cytyc Corp., Marlborough, MA). All of
these tests were performed on the samples collected in
PreservCyt liquid medium for liquid-based cytology
(ThinPrep). Informed consent was obtained from each
participant according to the ethics committee guidelines.
This study was approved by the CPP Sud-Med I (Comite´ de
Protection des Personnes Sud Me´diterrane´e I) under ref-
erence number 07 22.
The following assays were carried out and scored in
strict accordance with the manufacturer’s instructions.
Hybrid capture II
(HCII) (Digene): this assay detects 13 HR HPV genotypes
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). The
HCII test was performed using the automated HCII assay
system as described previously (13). For each specimen,
results were expressed in relative light unit/cutoff (RLU/
CO), corresponding to the ratio of the specimen lumines-
cence relative to the luminescence of the 1.0 pg/ml HPV16
standard provided with the kit. Samples with an RLU/CO
value C1 were considered HCII-HR positive. Samples
with an RLU/CO value \1.0 were considered HCII-HR
negative.
Digene HPV genotyping LQ Test (Digene LQ test)
analysis
The Digene LQ test utilizes probes for 18 HR HPV types
(i.e., HPV 16,18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 73, 82) that are the same as the respective RLB
probes, with minor modifications, and are immobilized on
color-coded beads. The Digene LQ test detection was
performed in the Luminex 100 IS System (Luminex Cor-
poration). In brief, 3B buffer was added to the HR HPV
beads to minimize the background in the final Luminex
read-out. Subsequently, GP5?/6?-PCR products were
added. Next, heat-denaturation, hybridization under strin-
gent conditions, and incubation with streptavidin-conju-
gated R-phycoerythrin detection conjugate were followed
by read-out according to the specified instrument settings,
resulting in MFI levels per HPV type for each specimen.
Statistical analysis
Two-sided P-values were calculated by Chi-square or
Fisher exact tests and placed on 2 9 2 contingency tables;
Cochran-Armitage test for trend was used for testing trend
binomial age proportions across levels of cervical intra-
epithelial neoplasia. All P-values \ 0.05 were considered
statistically significant. Calculations were performed using
SAS software (SAS Institute Inc., Cary, NC).
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Results
Table 1 shows the key characteristics of the 376 ASCUS
women. The mean age was 37 (± 11) years (116
were \30 years old, and 260 were C30 years old); 167
(44 %) were CIN2?, and 67 (18 %) were CIN3?. Digene
LQ was found positive in 349 (93 %) patients and negative
in 27 (7 %).
Figure 1 shows the histologic distribution among
patients in the age group \30 vs. those C30 years old.
There was no significant correlation between the rate of
histologic disease and age group: 25 % (29/116) of
\30-year-old patients were CIN2,1 compared with 27 %
(71/260) of C30-year-old patients. Similarly, 12 %
(14/116) of \30-year-old patients were CIN3 compared
with 20 % (51/260) of C30-year-old patients (p-value not
significant). The QIAGEN LQ test gave a positive result
for 349 patients, and thus, the concordance between Digene
LQ and HCII was 93 %.
Figure 2 shows the distribution of HPV genotypes using
Digene LQ in all patients, in patients aged under 30 years
old and in patients aged over 30 years old. Among HPV
genotypes, HPV16 was typed in 40 % of patients, HPV 18
in 7 %, HPV31 in 17 %, and HPV 56 in 7 %, and 18 % of
patients had mixed genotypes. Among the infections with
multiple HPV genotypes (N = 69), 52 (76 %) had two
HPV genotypes, 16 (23 %) had three HPV genotypes, and
1 (1 %) had five HPV genotypes. Patients aged over 30
more often had the HPV16 genotype than patients aged
under 30 (29 % vs. 11 %, Chi square test p \ 0.001).
Figure 3 shows the risk of CIN2? according to HPV
type. The risk of CIN2? when HPV 18 is positive is lower
than the probability associated with HPV16 or HPV31:
28 % vs. 58 % and 52 %, respectively (Chi square test,
p = 0.005 and p = 0.05, respectively). Similarly, the
Table 1 Key characteristics of
the 376 ASCUS? patients








Age; mean (± Sd) 37 (± 11) 36 (± 11) 37 (± 12) 39 (± 10)
Smear – N (%)
ASCUS 55 (15) 8 (5) 44 (36) 2 (2)
LSIL 169 (45) 87 (55) 48 (39) 35 (37)
HSIL 151 (40) 63 (40) 30 (24) 58 (61)
Cancer 1 (-) 0 (-) 1 (-) 0 (-)
Biopsy – N (%)
Normal 48 (13) 11 (7) 24 (20) 13 (14)
CIN1 161 (43) 79 (50) 54 (44) 28 (29)
CIN2 100 (27) 41 (26) 33 (27) 27 (28)
CIN3 65 (17) 27 (17) 11 (9) 27 (28)
Cancer 2 (-) 0 (-) 1 (-) 0 (-)
Qiagen HPV LQ – N (%)
Positive (all types) 349 (93) 146 (92) 118 (96) 85 (89)
Negative 27 (7) 12 (8) 5 (4) 10 (11)
HCII – N (%)



















Normal CIN1 CIN2 CIN3 Cancer
Age (years)
Rate of Patients
Fig. 1 Histologic distribution among patients in the \ 30- vs. C30-
year-old age groups. Bars show the rate of patients with ‘‘normal’’
histology (white bars), ‘‘CIN100 histology (light grey bars), or CIN 2,
CIN3, or cancer (black bars)) among patients under 30 years old on
one side, and over 30 years old on the other side. There was no
significant correlation between the rate of histologic disease and age
group (Cochran-Armitage test for trend p = 0.20)
1 Cervical intraepithelial neoplasia (CIN) is graded according to its
pathologic progress, from CIN 1 to CIN 3. CIN 2 ? stands for CIN 2
and CIN 3 grades.
Digene HPV genotyping LQ test 1145
123
probability of CIN3? when HPV18 is positive is lower
than probability associated with HPV16 but not with
HPV31: 3 %, 23 %, and 13 %, respectively (Chi square
test, p = 0.026 and p = 0.26, respectively) (Fig. 4).
Figure 5 shows the risk of CIN2? or CIN3? according
to the combination of HPV genotypes. The risk of CIN2?
when neither HPV16 nor HPV31 is detected is lower than in
all other cases (30 %; Chi square, p \ 0.05). Similarly, the
risk of CIN2 ? when neither HPV16 nor HPV18 is detected
is lower than in other cases except HPV18 negative and
HPV31 negative (38 % vs. 44 % respectively, Chi square
p = 0.10). The risk of CIN3? when HPV16 is detected, but
not HPV18, and the risk of CIN3? when HPV16 is detec-
ted, but not HPV31, are higher than in all other cases, except
when neither HPV18 nor HPV31 is detected (24 % and
25 % compared with 20 %, respectively).
Table 2 shows the age distribution of HPV genotypes
among CIN1 and CIN2? patients. A significant difference
in age distribution was observed in patients with high-risk
HPVs (by pooling HPV16, HPV18, HPV31, and other HPV
types) (p = 0.04): an increasing rate of CIN2? was
observed with increasing age (inversely for CIN 1
patients). Similarly, a significant difference in age was
observed in patients with ‘‘other’’ HPV types (other than
HPV16, HPV18, or HPV31) (p = 0.04).
Discussion
This multicenter study evaluated for the first time the
clinical utility of HPV genotyping using the recently
developed Digene LQ assay (in atypical squamous cells
of undetermined significance, and HCII-positive women
referred for colposcopy in three European centers [France,
Spain, and Italy]). The distribution of genotypes using this
assay indicated, as expected, that HPV types 16, 31/33, 18
and mixed genotypes are the most prevalent, in accor-
dance with previously reported results [23].
The recent ASCCP guidelines recommend the use of





























Fig. 3 Risk of CIN2?
according to HPV type. Bars
show the rate of patients with
the corresponding HPV type
among patients with CIN2?
histology. Groups were
compared with each other;
chi-square test p-values are












All Patients <30 30
HPV Genotypes
Rate of PatientsFig. 2 Distribution of HPV
genotypes using LQ. Black bars,
all 376 patients; white bars,
patients aged under 30; grey
bars, patients aged over 30.
Patients aged over 30 more
often had HPV 16 genotype
than patients aged under 30
(29 % vs. 11 %, chi-square test
p \ 0.001)
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referral to colposcopy based on HPV16- and/or HPV18-
positive results [13]. Moreover, screening with HPV DNA
testing for oncogenic genotypes followed by cytological
triage has attractive features that may serve the screening
needs for a post-vaccination era in the US. However, the
methods for HPV typing should be specifically validated
with CIN2? as a clinical endpoint, and comparatively
with other methods. This would be a prerequisite for the
use of genotyping assays in cervical cancer screening
algorithms. Particularly in light of the recent FDA
approval of an HPV genotyping test, this study focused
on how typing could be used to assist clinical decisions
and whether its implementation would be cost-effective
[24, 25].
This new sequence-specific Digene LQ test is fast and
efficient and allows direct HPV genotyping of 18 HR types
by PCR, compared to traditional non-sequence-specific test
methods. The utility of this method was evaluated on
cervical samples positive for HR HPV by the HCII

























Fig. 4 Risk of CIN3?
according to HPV type. Bars
show the rate of patients with
the corresponding HPV type
among patients with CIN3?
histology. Groups were
compared with each other;
chi-square test p-values are





















HPV16+/HPV18- HPV16-/HPV18- HPV16+/HPV31- HPV16-/HPV31- HPV31+/HPV18- HPV31-/HPV18-
CIN2+ CIN3+
Fig. 5 Risk of CIN2? and
CIN3? according to HPV type.
Bars show the rate of patients
with the presence or absence of
corresponding HPV types: ‘‘?’’
stands for presence of the HPV
type, ‘‘-’’stands for absence of
the HPV type (HPV16?/
HPV18- stands for presence of
HPV 16 and absence of HPV
18). White bars are CIN2?
patients, and black bars are
CIN3? patients





HPV 16/18/31 Positive \20 2 (67 %) 1 (33 %) 0.17
20-29 25 (49 %) 26 (51 %)
30-39 29 (40 %) 43 (60 %)
40-49 16 (38 %) 26 (62 %)
C50 5 (36 %) 9 (64 %)
Other HPV \20 1 (100 %) 0 (-) 0.04
20-29 24 (71 %) 10 (29 %)
30-39 19 (73 %) 7 (27 %)
40-49 12 (46 %) 14 (54 %)
C50 8 (53 %) 7 (47 %)
Overall HPV Positive \20 3 (75 %) 1 (25 %) 0.04
20-29 49 (58 %) 36 (42 %)
30-39 48 (49 %) 50 (51 %
40-49 28 (41 %) 40 (59 %)
C50 13 (45 %) 16 (55 %)
Digene HPV genotyping LQ test 1147
123
Among women with ASCUS cytology, the relative
probability of pre-cancer is higher in HR HPV-positive
women than HR HPV-negative women [20]. Interestingly,
using the Digene LQ, the probability of being CIN2?
when having HPV16 is 58 %, similar to the probability
associated with HPV31, 52 %, and the probability is 28 %
if HPV18 positive. The probability of being CIN3? when
having HPV16 is 23 % (the probability is 3 % if HPV18
positive, and 13 % if HPV31 positive). The relative prob-
ability of CIN2? when being HPV16?/HPV18- is 58 %
(the probability of CIN3? is 24 %). Similarly, the proba-
bility of CIN2? when being HPV16?/HPV31 is 59 % (the
probability of CIN3? is 25 %), and the probability of
CIN2? when being HPV31?/HPV18- is 54 % (the prob-
ability of CIN3? is 13 %).
These data are similar to those reported in the recently
published ATHENA study: HPV16/HPV18? women had a
greater probability of CIN 2 or worse compared with
pooled HR-HPV? and HR-HPV- women (24.4 %, 14.0 %,
and 0.8 %, respectively) [20].
Among HR-HPV-positive women, risk of disease likely
increases over time, as has been reported for genotypes 16
and 18 by Khan et al. [12]. Up to now, the risk threshold
for performing colposcopy in response to specific cytology
and HPV test results has not been defined. Castle et al.
suggested that women with a probability for CIN3? dis-
ease of 10 % or greater over two years should be investi-
gated [26].
While all women with ASCUS cytology testing positive
for HR HPV should be referred for colposcopy, the results
from this study demonstrate that those women with
ASCUS cytology testing positive with HPV16 and/or 18
and 31 are at a particularly high risk for C CIN3 disease,
reinforcing the need for immediate colposcopy and more
intense follow-up, particularly in the case of a negative
colposcopy. These findings corroborate those of other
studies [27, 28].
This study points out the greater probability of CIN2 and
CIN3 for patients testing positive for HPV31. HPV31 is a
more prevalent type than HPV18 in the ASCUS population
in European countries [19, 29]. Notably, this study high-
lights that the probability of HPV31 is greater than that of
HPV18. This was also observed by So¨derlund et al. [30]:
an odds ratio of the risk of CIN2? or CIN3? was 3.79
and 2.83 for HPV31 vs. 1.46 and 0.82 for HPV18,
respectively.
Another prevalent genotype in our population was
HPV56, found in the same proportion as HPV18.
Regarding the laboratory technical characteristics, this
assay uses multiplex, bead-based xMAP technology and an
automated, high-throughput read-out by either the Liqui-
Chip 200 workstation (QIAGEN, Hilden, Germany) or
Luminex 100 IS System (Luminex Corporation, Austin,
TX). The test was developed for identification of the 18 HR
HPV genotypes associated with cervical cancer using
GP5?/6?-PCR products. The Digene LQ Test and the
RLB assay have been reported to have a high level of
agreement in detection and genotyping of 18 HR HPV
types in HCII-positive specimens [21].
Conclusions
The Digene LQ, a new sequence-specific HC sample
preparation is fast and efficient and allows high-throughput
genotyping of 18 HR HPV types by PCR compared to
traditional non-sequence-specific sample preparation
methods. This study showed that HPV types 16, 31, 33, 18
and mixed genotypes are the most prevalent genotypes and
that ASCUS women who are HPV16 positive have the
highest probability of CIN2? and CIN3?.
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